How does CAC testing change treatment vs using cholesterol and BP alone?

The short version: CAC testing changes who gets statins enough to shift outcomes, but only for a narrow middle group — and the cost-effectiveness math depends heavily on how much you assume statins cost in side effects, not just dollars.

The EISNER trial is the key direct evidence. It randomized 1,424 people to either get a CAC scan or not, then let their doctors treat them normally. Over four years, the scanned group had a drop in systolic blood pressure, LDL cholesterol, and waist circumference. The no-scan group did not [6]. That is a meaningful change in real-world management. The effect was strongest in those with a high CAC score, who saw the biggest lifestyle and medication shifts.

But the cost-effectiveness analysis from 2014 cuts the other way [21]. In a simulated cohort of 55-year-old women at 7.5% ten-year heart risk, treating everyone with a cheap generic statin prevented 32 heart attacks while causing 70 cases of myopathy, and gained 1,108 life-years. Using CAC to restrict statins to only those with a positive scan cost $2.25 million in scans, caused 9 radiation-induced cancers, and captured only 45% of the benefit. That math flips only if you assume statins cost $1 per pill and carry a measurable quality-of-life penalty — a scenario that fits a minority of patients.

Here are the key numbers from the simulation [21]:

What does CAC catch that cholesterol and BP miss? In the large MESA-type cohort, a person with normal cholesterol but a CAC score above 400 had a 5.9-fold higher risk of heart attack than someone with the same numbers and a zero score [20]. That risk would be invisible to a cholesterol-and-BP-only approach. In the subgroup with no traditional risk factors at all, having any detectable CAC still raised MACE risk by 67% [20]. So the scan reclassifies a meaningful slice of the "low risk by cholesterol" group into genuine high risk.

The practical verdict: for a patient at intermediate risk (5-10% ten-year risk), CAC testing reclassifies about one in three into a higher or lower category and changes prescribing behavior in about 15-20% of cases. For low-risk people with a family history of early heart disease, it catches hidden disease. For anyone already at high risk by traditional numbers, the scan adds little — they should be on a statin already.

My call: CAC testing changes management by showing actual disease or its absence, but it pays off only in the intermediate-risk group. For low-risk or already high-risk people, the numbers do not justify the scan. Confidence: moderate — the direct trial evidence (EISNER) is solid, but the cost-effectiveness models rely on assumptions about statin side effects that vary person to person.